Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD9 | Q9H8M2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 5/20 | 0.41 |
| ▸ | TAF1 | P21675 | 2/20 | 0.41 |
| ▸ | BRPF1 | P55201 | 2/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.41 |
| ▸ | CECR2 | Q9BXF3 | 2/20 | 0.41 |
| ▸ | HTR1A | P08908 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15344922 | 1.00 | BRD9 (0.44) | BRD9MAPTHTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL29721035 | 0.98 | BRD9 (0.43) | BRD9MAPTHTR2AHTR2CHTR2B | |
| Trifluoroacetic Acid SCHEMBL29721133 | 0.87 | STING1 (0.39) | BRD9MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL4772542 | 0.85 | BRD9 (0.44) | BRD9MAPTHTR2AHTR2CHTR2B | |
| SCHEMBL30441185 | 0.84 | BRD9 (0.38) | BRD9BRD4TAF1BRPF1CREBBP | |
| SCHEMBL28001902 | 0.78 | STING1 (0.38) | MAPTHTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL23425580 | 0.77 | HTR2A (0.48) | HTR2AHTR2CHTR2BHTR1ADRD2 | |
| SCHEMBL15341744 | 0.77 | HTR2A (0.44) | HTR2AHTR2CHTR2BHTR1ADRD2 | |
| SCHEMBL28948256 | 0.77 | HTR2A (0.38) | MAPTHTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL30171226 | 0.77 | HTR2A (0.38) | MAPTHTR2AHTR2CHTR2BHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LTD (GB) | 2026-04-02 | — | — | US | disclosed |
| US-20250255857-A1 | METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER | FOGHORN THERAPEUTICS INC. | 2025-08-14 | — | — | US | disclosed |
| EP-4587126-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2025-07-23 | — | — | EP | disclosed |
| WO-2024057021-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2024-03-21 | — | — | WO | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| EP-4263511-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | Amphista Therapeutics Ltd (GB) | 2023-10-25 | — | — | EP | disclosed |
| CN-116897150-A | Novel bifunctional molecules for protein-targeted degradation | 安菲斯塔治疗有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-116322780-A | Compounds and uses thereof | 福宏治疗公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-115894479-A | Polycyclic derivative, composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115279370-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2022-11-01 | — | — | CN | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| CN-114641473-A | BRD9 bifunctional degradation agent and use method thereof | 诺华股份有限公司 | 2022-06-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255857-A1 | METHODS OF TREATING ANDROGEN RECEPTOR-INDEPENDENT PROSTATE CANCER | AR, ESRRB, ESRRA | BRD9 692/4885MAPT 2965/4885HTR2A 1729/4885 |
| US-20260092061-A1 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | BCL9L, RBBP9, BRD9 | BRD9 3/4885MAPT 3721/4885HTR2A 3390/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | BRD9 290/4885MAPT 1498/4885HTR2A 4196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.